Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for ORIC

Show aggregate ORIC holdings

News associated with ORIC

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Moderate Buy” from Analysts

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target […] - 2025-09-19 03:15:02

Brokerages Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $17.63

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month […] - 2025-08-28 03:12:47

JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price

Oric Pharmaceuticals (NASDAQ:ORIC – Free Report) had its price target decreased by JPMorgan Chase & Co. from $20.00 to $17.00 in a research report sent to investors on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. ORIC has been the subject of a number of other reports. Oppenheimer lowered […] - 2025-08-15 04:52:49

Victory Capital Management Inc. Has $838,000 Position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC)

Victory Capital Management Inc. raised its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 54.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 150,260 shares of the company’s stock after buying an additional 52,760 shares during the period. Victory Capital Management Inc.’s […] - 2025-08-01 05:01:17

Arizona State Retirement System Purchases New Position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC)

Arizona State Retirement System purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) during the first quarter, Holdings Channel reports. The institutional investor purchased 10,088 shares of the company’s stock, valued at approximately $56,000. A number of other hedge funds have also modified their holdings of ORIC. Vanguard Group Inc. increased its […] - 2025-07-24 04:38:53

LADENBURG THALM/SH SH Initiates Coverage on Oric Pharmaceuticals (NASDAQ:ORIC)

LADENBURG THALM/SH SH assumed coverage on shares of Oric Pharmaceuticals (NASDAQ:ORIC – Free Report) in a report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $15.00 price target on the stock. Several other equities research analysts have also recently weighed in on ORIC. Oppenheimer decreased their price objective on Oric […] - 2025-07-11 02:36:47

Brokerages Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $19.17

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have received an average rating of “Buy” from the nine brokerages that are covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock […] - 2025-07-09 02:33:02

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up After Insider Buying Activity

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares gapped up prior to trading on Tuesday following insider buying activity. The stock had previously closed at $10.00, but opened at $10.63. Oric Pharmaceuticals shares last traded at $10.87, with a volume of 484,723 shares. Specifically, Director Angie You acquired 26,597 shares of the firm’s stock […] - 2025-06-25 02:22:47

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 54.5% during the fourth quarter, Holdings Channel reports. The fund owned 35,579 shares of the company’s stock after purchasing an additional 12,545 shares during the quarter. UBS AM a […] - 2025-06-13 04:32:47

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Recommendation of “Buy” by Analysts

Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have been assigned an average rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have covered the stock […] - 2025-06-11 03:08:48

Thursday's ETF Movers: XBI, URA

In trading on Thursday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 1.9% on the day. Components of that ETF showing particular strength include shares of Oric Pharmaceuticals, up about 33.8% and shares of Replimune Group, up about 9.6% on the day. And un - 2025-05-29 12:59:01

Janus Henderson Group PLC Makes New Investment in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Janus Henderson Group PLC acquired a new stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 14,600 shares of the company’s stock, valued at approximately $118,000. Several other institutional investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a […] - 2025-05-26 04:51:01

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $19.17

Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have been assigned an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have updated their coverage on […] - 2025-05-22 05:30:55

Tower Research Capital LLC TRC Purchases 13,384 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Tower Research Capital LLC TRC lifted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 1,048.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,661 shares of the company’s stock after purchasing an additional 13,384 shares during the quarter. […] - 2025-05-09 05:21:00

MetLife Investment Management LLC Purchases 5,530 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

MetLife Investment Management LLC grew its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 15.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,608 shares of the company’s stock after acquiring an additional 5,530 shares during the period. MetLife Investment […] - 2025-05-07 05:28:51

HC Wainwright Reiterates Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $21.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 316.67% from the stock’s previous close. Other analysts […] - 2025-05-07 02:58:49

XTX Topco Ltd Has $210,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

XTX Topco Ltd increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 120.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,966 shares of the company’s stock after acquiring an additional 14,209 shares during the period. XTX […] - 2025-04-28 05:11:12

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $18.86

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received a consensus recommendation of “Buy” from the nine brokerages that are currently covering the company, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year […] - 2025-04-25 02:32:47

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 6.9% during the fourth quarter, HoldingsChannel reports. The fund owned 186,430 shares of the company’s stock after buying an additional 12,042 shares during the period. Wellington Management Group LLP’s holdings in ORIC Pharmaceuticals were worth $1,504,000 at […] - 2025-04-14 04:45:06

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Consensus PT from Brokerages

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has been assigned an average rating of “Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in […] - 2025-03-31 02:32:43

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Better-Than-Expected Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $7.85, but opened at $8.57. ORIC Pharmaceuticals shares last traded at $7.99, with a volume of 78,926 shares traded. The company reported ($0.51) EPS for the […] - 2025-02-21 04:56:45

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Buy” from Analysts

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […] - 2025-02-11 06:30:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ORIC holdings

Date	Number of ORIC Shares Held	Base Market Value of ORIC Shares	Local Market Value of ORIC Shares	Change in ORIC Shares Held	Change in ORIC Base Value	Current Price per ORIC Share Held	Previous Price per ORIC Share Held
2025-09-26 (Friday)	10,689	USD 118,862	USD 118,862
2025-09-25 (Thursday)	10,689	USD 111,272	USD 111,272	0	USD -535	USD 10.41	USD 10.46
2025-09-24 (Wednesday)	10,689	USD 111,807	USD 111,807
2025-09-17 (Wednesday)	10,619	USD 111,712	USD 111,712	0	USD -4,035	USD 10.52	USD 10.9
2025-09-16 (Tuesday)	10,619	USD 115,747	USD 115,747
2025-09-12 (Friday)	10,549	USD 113,718	USD 113,718
2025-09-11 (Thursday)	10,549	USD 114,562	USD 114,562

Share Trades of ORIC by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-05-23	BUY	47			6.350*		5.92
2025-05-19	SELL	-47			5.140*		5.94 Profit of 279 on sale
2025-05-15	SELL	-141			4.740*		5.99 Profit of 844 on sale
2025-05-12	SELL	-47			5.410*		6.04 Profit of 284 on sale
2025-05-09	SELL	-47			5.080*		6.06 Profit of 285 on sale
2025-04-30	SELL	-47			5.710*		6.17 Profit of 290 on sale
2025-04-24	SELL	-94			5.190*		6.27 Profit of 589 on sale
2025-04-17	SELL	-47			4.770*		6.48 Profit of 304 on sale
2025-04-15	SELL	-141			5.040*		6.58 Profit of 928 on sale
2025-04-14	SELL	-141			5.110*		6.63 Profit of 935 on sale
2025-04-09	SELL	-188			4.690*		6.86 Profit of 1,291 on sale
2025-04-07	SELL	-329			4.590*		7.07 Profit of 2,325 on sale
2025-04-04	SELL	-480			4.880*		7.16 Profit of 3,438 on sale
2025-03-31	BUY	48			5.580*		7.39
2025-03-19	SELL	-96			7.470*		7.79 Profit of 748 on sale
2025-03-14	SELL	-288			7.790*		7.79 Profit of 2,244 on sale
2025-03-13	SELL	-96			7.700*		7.80 Profit of 749 on sale
2025-03-12	SELL	-1,632			8.000*		7.77 Profit of 12,688 on sale
2025-03-07	SELL	-96			8.000*		7.77 Profit of 746 on sale
2025-03-06	SELL	-144			7.850*		7.75 Profit of 1,116 on sale
2025-03-03	SELL	-48			7.640*		0.00

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ORIC

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer